DIA-based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia
This study identifies IDH2 as a targetable regulator of drug resistance in CML by analyzing proteomic changes in resistant K562 cells.